Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening

Applied Health Economics and Health Policy

Volumn 13, Issue 1, 2015, Pages 95-107

  Huh, Warner K ^a   Williams, Erin ^b   Huang, Joice ^c   Bramley, Tommy ^b   Poulios, Nick ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b XCENDA   (United States)

^c Roche Molecular Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MIDDLE AGED; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECONOMICS; GENETIC SCREENING; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; PROBABILITY; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GENETIC TESTING; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MARKOV CHAINS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84943589185     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0135-4     Document Type: Article

References (43)

1. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(Suppl 10):K29–41.
2. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S3/78–89.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.
4. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7):475–87.
5. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072–9.
6. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–90.
7. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr., Cuzick J. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2012;208(3):184e1–e11.
8. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582–9.
9. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–72.
10. Perkins RB, Anderson BL, Gorin SS, Schulkin JA. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med. 2013;45(2):175–81.
11. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol Oncol. 2010;119(2):237–42.
12. Wright TC, Jr., Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46e1–e11.
13. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johansson B. Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer. 2009;101:511–7.
14. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV-type distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;2006(24S):S3/26–S3/34.
15. Cuzick J, Cox T, Zhang G, et al. Human papillomavirus testing for triage of women with low-grade squamous lesions. Int J Cancer. 2013;132(4):959–66.
16. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004;36(1):11–9.
17. Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91(3):530–6.
18. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003;106(6):896–904.
19. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9(1):37–48.
20. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158–71.
21. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer. 2007;2:15.
22. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169(2):235–40.
23. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14–9.
24. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30(Suppl 5):F157–67.
25. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, et al. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health. 2010;10:734.
26. Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A, Iskandar R, et al. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics. 2010;28(11):995–1000.
27. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71(2):159–65.
28. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review, 1975–2007. Bethesda, MD: National Cancer Institute; 2010 (based on November 2009 data submission). Available http://seer.cancer.gov/csr/1975_2007. 2010.
29. Denny L, Wright TC. Glob. libr. women’s med. Strategies for overcoming the barriers to cervical cancer screening in low-resource settings (ISSN: 1756-2228). 2009. doi:10.3843/GLOWM.10022.
30. Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: population based cohort study. Bmj. 2012;344:e900.
31. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1–27.
32. Guedes AC, Zeferino LC, Syrjanen KJ, Brenna SM. Short-term outcome of cervical intraepithelial neoplasia grade 2: considerations for management strategies and reproducibility of diagnosis. Anticancer Res. 2010;30(6):2319–23.
33. Stratton KR, Durch JS, Lawrence RS, editors. Committee to Study Priorities for Vaccine Development Division of Health Promotion and Disease Prevention Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking. Washington: National Academies Press; 2000.
34. Severens JL, Milne RJ. Discounting health outcomes in economic evaluation: the ongoing debate. Value Health. 2004;7(4):397–401.
35. Smith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care. 2001;17(2):236–43.
36. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835–42.
37. Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial—the HPV FOCAL Study. Br J Cancer. 2012;107(12):1917–24.
38. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014;120(13):2032–8.
39. From the Centers for Disease Control. Hysterectomy prevalence, cervical cancer deaths. Jama. 1992;267(7):914.
40. Schmidt MA, Gold R, Kurosky SK, Daley MF, Irving SA, Gee J, et al. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006–June 2011. J Adolesc Health. 2013;53(5):637–41.
41. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78–88.
42. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012;344:e670.
43. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bull World Health Organ. 2001;79(10):954–62.